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The need for international collaboration in rodent pathology has evolved since the 1970s, and 
was initially driven by the new field of toxicologic pathology. First initiated by the World Health 
Organization’s International Agency for Research on Cancer for rodents, it has evolved to 
include pathology of the major species (rats, mice, guinea pigs, nonhuman primates, pigs, dogs, 
fish, rabbits) used in medical research, safety assessment and mouse pathology. The 
collaborative effort today is driven by the needs of the regulatory agencies in multiple countries, 
and by needs of research involving genetically engineered animals, for “basic” research, and for 
more translational preclinical models of human disease. These efforts led to the establishment of 
an international rodent pathology nomenclature program. Since that time, multiple collaborations 
for standardization of laboratory animal pathology nomenclature and diagnostic criteria have 
been developed, and just a few are described herein. Recently, approaches to a nomenclature that 
is amenable to sophisticated computation have been made available and implemented for large-
scale programs in functional genomics and ageing. Most terminologies continue to evolve as the 
science of human and veterinary pathology continues to develop, but standardization and 
successful implementation remain as critical for scientific communication, now as ever in the 
history of veterinary nosology. 
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History of International Laboratory Animal Pathology Nomenclature  
The use of any standardized nomenclature for rodent pathology perhaps began in the 1970s with 
the publication of a series of tumor pathology books (on mice, rats and hamsters) by the 
International Agency for Research in Cancer (IARC), World Health Organization (WHO), Lyon, 
France. Dr. Vladimir Turusov, a medical pathologist, was the initial editor of a book series and 
chapter authors were invited from Europe, Japan and the USA (Turusov 1973, 1980, 1983, 1990, 
1994). In the 1990s, Ulrich Mohr was editor for the second and third IARC series on rats and 
mice (Mohr 1997, 2001). In these series, international committees of pathologists prepared 
monographs on tumors of each organ system for rats and one book for mice. In the early 1990s, 
committees for nomenclature of tumors and non-proliferative lesions for each organ system of 
rats and mice were established as Guides for Toxicologic Pathology, a system of standardized 
nomenclature and diagnostic criteria (SNNDC), by a collaboration of the Armed Forces Institute 
of Pathology (AFIP), American Registry of Pathology (ARP) and the Society of Toxicologic 
Pathology (STP). The first published series was on rat pathology and was published by the AFIP 
and are presently online (https://toxpath.org/ssndc.asp). From 1983 to1996, The International 
Life Sciences Institute sponsored a series of thirteen Monographs on Pathology of Laboratory 
Animals led by T. C. Jones, U. Mohr and R. D. Hunt (Jones et al; 
https://link.springer.com/bookseries/780). During the same period, the National Toxicology 
Program (NTP) staff pathologists, contractors and collaborators published 2 books on rat and 
mouse pathology (Boorman et al. 1990; Maronpot 1999). These efforts led to the establishment 
of an international rodent pathology nomenclature program (International Harmonization of 
Nomenclature and Diagnostic Criteria – INHAND) involving several of the national societies of 
toxicologic pathology. 
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International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) for use 
in Toxicology Safety Assessment 
In 2005, the Strategic and Regulatory Policy Committee (SRPC) of the STP determined 
that there was need for a revision of the earlier Standardized System of Nomenclature and 
Diagnostic Criteria (SSNDC) guides. The European Society of Toxicologic Pathology (ESTP), 
in conjunction with the Registry of Industrial Toxicology Animal-data (RITA), endorsed the 
proposal in late 2005.  In 2006, the Japanese Society of Toxicologic Pathology (JSTP) and the 
British Society of Toxicologic Pathology (BSTP) joined the initiative, providing a truly global 
participation.  Members of these major Societies of Toxicologic Pathology (JSTP, BSTP, ESTP 
and STP) and RITA are now engaged in an international collaborative effort (INHAND) to 
codify and publish uniform nomenclature for both proliferative and non-proliferative lesions in 
laboratory rodents.  Several features unique to this effort include: 1) a truly international scope, 
2) implementation of an open comment period allowing a wide group of toxicologic pathologists 
the opportunity to provide input, 3) inclusion of neoplastic and nonneoplastic terminology, and 
4) availability in a web-based format along with publication in society journals. Project oversight 
is provided by the Global Editorial and Steering Committee (GESC) which consists of members 
from each of the major Societies of Toxicologic Pathology (Figure 1).  Each rodent organ system 
or non-rodent species organ working group consists of a chairperson and members from each of 
the major societies of toxicologic pathology, drawing upon a diversity of experience and 
background with individuals from industry, academia, and government.   
The Rodent Organ Working Groups (?) (OWGs) have the responsibility to prepare the 
nomenclature guidelines for both proliferative and non-proliferative lesions of rats and mice for 
their assigned organ system – 15 total systems.  The Non-rodent Species Working Groups 
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(NRWGs) cover terminology specific to a species as well as noting diagnostic criteria that may 
be different from rodents for common lesions.  The NRWGs include non-human primate, dog, 
minipig, rabbit and fish.  In addition to lesions which occur spontaneously, the groups are asked 
to determine if there are common, xenobiotic-induced lesions for which standardized 
nomenclature might be needed.  The working groups draw heavily from existing nomenclature 
documents, websites, and publications including prior work of the RITA and the SSNDC.  For 
each diagnostic entity, the working groups select a preferred diagnosis and acceptable alternative 
diagnoses, provide diagnostic criteria and differential diagnosis, prepare representative 
photomicrographs, and also provide a comment section with key references.  In general, working 
groups develop nomenclature that is primarily descriptive in nature and denote findings which 
can be documented from the review of routine histologic specimens.  Incorporating specific 
diagnostic entities such as an infectious disease or that imply a process that cannot be ascertained 
from routine histologic specimens (e.g., phospholipidosis) is generally not recommended.  
Finalized nomenclature is available to toxicologic pathologists, and the broader scientific 
community, in both electronic and print forms. The print-based publications are available in the 
toxicologic pathology journals: Toxicologic Pathology, the official journal of STP, BSTP and 
ESTP (http://journals.sagepub.com/home/tpx) and the Journal of Toxicologic Pathology which is 
the official journal of JSTP (https://www.jstage.jst.go.jp/browse/tox). Electronic access is via the 
global open Registry Nomenclature Information System (goRENI) website 
(https://www.goreni.org) or the journal websites (https://www.toxpath.org/inhand.asp#pubg or 
https://www.jstage.jst.go.jp/browse/tox). 
 Substantial progress has been made to date – 12 of the 15 rodent organ systems have 
been published:  Respiratory System (Renne et al. 2009), Hepatobiliary System (Thoolen et al. 
	 9	
2010), Urinary System (Frazier et al. 2012), Nervous System (Kaufmann et al. 2012), Mammary, 
Zymbal’s, Preputial and Clitoral Glands (Rudmann et al. 2012), Male Reproductive System 
(Creasy et al. 2012), Soft Tissue (Greaves et al. 2013), Integument (Mecklenburg et al. 2013), 
Female Reproductive System (Dixon et al. 2014), Digestive System (Nolte et al. 2016), 
Cardiovascular System (Berridge et al. 2016), and Skeletal System and Tooth (Fossey et al. 
2016). To address consistent terminology for cell death, Recommendations from an 
Apoptosis/Necrosis Working Group was published by Elmore et al. in 2016.  The Endocrine and 
Special Senses Systems and the Hematopoietic and Lymphoid System are scheduled for 
publication in 2018/2019.  
An important aspect of the INHAND project is utilization of goRENI.  ESTP offered 
access to an open version of goRENI to serve as a platform. Access to goRENI is restricted to 
members of the participating STPs (Vahle et al. 2006; Mann et al. 2012).  Once access is granted, 
pathologists can navigate by organ systems and select a diagnosis they would like to view.  
Within the goRENI system, each diagnostic entity is referred to as a manuscript.  An example is 
provided in Figure 2 of the written information and photographic illustrations provided for a 
kidney oncocytoma. 
Although the published INHAND nomenclature for each organ system is expected to be 
very comprehensive, it is recognized that additional lesions may need to be included, 
inaccuracies corrected as they become apparent, or changes to terminology made based on new 
scientific information. To address this, a formal change control process was implemented in 
2013 and is available on www.goreni.org and each pathology Society website.  Society members 
are encouraged to submit recommendations for changes to the nomenclature systems and provide 
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justifications for such changes through this mechanism. Updates will be posted on goRENI, and 
this will be the source for the most current information. 
The GESC and STP, BSTP, ESTP, and JSTP leadership recognize the significant efforts 
of all of those serving on the rodent OWGs and NRWGs, and look forward to working with the 
global toxicologic pathology community as additional systems are drafted, reviewed, and 
completed.  The international scope and review of the INHAND documents will provide a strong 
framework for use by pathologists and regulatory agencies that are engaged in the safety 
assessment of drugs, biologics, and chemicals. 
 
Standard for Exchange of Nonclinical Data (SEND) 
SEND is a standardized procedure for submitting data from nonclinical studies to the 
Food and Drug Administration (FDA) electronically and in a standardized format (Keenan and 
Goodman 2014).  During 2011, INHAND GESC representatives attended meetings with 
representatives of the FDA Center for Drug Evaluation and Research (CDER), Clinical Data 
Interchange Standards Consortium (CDISC), and the National Cancer Institute (NCI) Enterprise 
Vocabulary Services (EVS) to initiate integration of INHAND terminology as the preferred 
terminology for SEND.  INHAND GESC representatives work with the SEND Controlled 
Terminology (CT) committee to provide definitions for base processes and modifiers associated 
with the INHAND published terminology. Any issues or questions are presented to the full 
GESC and/or appropriate INHAND Working Group for resolution.  The initial list for the SEND 
codelist of nonneoplastic (NONNEO) microscopic pathology contains terms from published 
INHAND organ systems.  The list will continue to grow as INHAND publishes additional organ 
systems.  Some terms on the NONNEO codelist may look different from how they have been 
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presented in the INHAND publications.  Terms on the NONNEO codelist are mostly generic and 
can be used across tissues, where appropriate.  INHAND published terms have been modified to 
fit the SEND standard in some cases by being broken into base process and modifiers.  For 
example, the INHAND term Necrosis, zonal would be separated into NECROSIS for population 
in MISTRESC (Microscopic Standardized Result) and ZONAL in MIDISTR (Microscopic 
Distribution).  Tissue specific terms from INHAND are included on the NONNEO codelist when 
it is important to use the exact term representing a spectrum of tissue changes (example – focus 
of cellular alteration).  In the process of mapping terms from INHAND to SEND, some 
inconsistencies have been noted for the same term across several organ systems (example – 
thrombus vs thrombosis).  These will be harmonized using the new change control process and 
the most current terminology will be available on the goRENI website.  An example of a 
nomenclature map with INHAND terminology is shown in Figure 3.  The most current SEND 
controlled terminology can be found at the NCI EVS site: 
https://evs.nci.nih.gov/ftp1/CDISC/SEND/. 
 
National Toxicology Program (NTP) Nonneoplastic Lesion Atlas 
Assessing the carcinogenicity of agents of concern in its rodent models has been at the 
core of the NTP’s testing program; however, in recent years, the NTP has increased its focus on 
nonneoplastic lesions, many of which have been linked to occupational or environmental 
exposures. Diagnosing nonneoplastic lesions in toxicity studies presents a challenge in that there 
can be variation in terminology and diagnostic strategy. With nonneoplastic lesions, there are 
often several related lesions present concurrently, such as inflammation, necrosis or 
degeneration, fibrosis, and regeneration. Some pathologists record each lesion individually, 
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while others record the predominant lesion, or the primary process, and describe other lesions or 
features in the pathology narrative. Additionally, it can be difficult to determine which is the 
primary lesion, or which is the primary process. Also, the terminology used by different 
pathologists can vary based on training, experience, and personal opinion. In an effort to 
standardize the nomenclature and diagnostic strategy for NTP studies, the NTP created the 
Nonneoplastic Lesion Atlas (NNLA). The goal of the NNLA is to create a more consistent 
database of nonneoplastic lesions, which would allow comparison across studies, facilitate data 
mining, and allow for the generation of historical control data for some nonneoplastic lesions. 
The NNLA is an online guide for the diagnosis and recording of nonneoplastic lesions in 
studies conducted by the NTP. It is organized by organ system and subdivided by tissue. Each 
page discusses a single lesion and provides recommendations for terminology and diagnostic 
strategy. The NNLA also provides references, links to related lesions, other useful information 
about the lesions, and thousands of zoomable photos of the lesions. The NTP has made every 
effort to be consistent with the terminology presented in the INHAND in Rats and Mice . The 
NNLA can be a valuable supplement to the INHAND documents. 
Since the NNLA is an online document, it can (and will) be updated as the field of 
toxicologic pathology changes. It is searchable, downloadable, and available at 
https://ntp.niehs.nih.gov/nnl/. Though its main purpose is as a guide for toxicologic pathologists 
reading NTP studies, it is available free for public use around the world. It can be used by any 
toxicologic or pathology laboratory wanting to standardize their own database, by other scientists 
evaluating tissues, and by students as a training aid. 
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National Cancer Institute (NCI) Mouse Models of Human Cancer Consortium (MMHCC 
Nomenclature) 
The advent of genetic engineering opened up a new era in animal research. Suddenly, the 
cell and molecular biologist could determine the effect of genetic mutations and selected 
engineered mutations in living mammalian organisms. Testing your mutation in a mouse fulfilled 
the “modern Koch’s postulates”. Rodents were once valued in cancer research because they 
spontaneously developed neoplasia in specific organs. In fact, they led the way to the 
understanding of oncogenic viruses. However, after investigators became equipped with an 
endless list of genes, they wished to know whether their gene(s) caused cancer in their favorite 
organ and whether or not their tumors resembled the comparable human tumor. 
The NCI started exploring these questions by organizing and convening a Breast Cancer 
Consensus Meeting in Annapolis Maryland in 1999. The meeting included oncologists, 
modelers, breast pathologists and comparative or veterinary pathologists. The pathologists were 
tasked with developing a taxonomy and vocabulary that could be used to compare and contrast 
breast cancers in human and genetically engineered mice. The pathologists responded with a 
recommended taxonomy and a landmark paper (Cardiff et al. 2000). 
With NCI’s organization of the Mouse Models of Human Cancer Consortium groups, 
under the NCI Division of Cancer Biology’s extramural grant program, each of nine organ 
systems were tasked with developing comparable (human and mouse) consensus pathology 
meetings. In preparation, the MMHCC met with the NCI vocabulary informatics experts to 
discuss the classification and nomenclature for each organ system. This exercise was 
accompanied by consensus meetings for each organ composed of committees of medical and 
veterinary pathologists, and PhD researchers from various medical and veterinary colleges, 
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government, and private research institutes. In some cases, the meetings were repeated with 
follow-up meetings. In some instances, specific subsets of issues, such as preneoplasia, were 
addressed (Cardiff et al. 2006). 
The strength of the resulting nomenclatures was that the similarities and differences in 
the anatomy, physiology, and pathology of diseases were compared and contrasted by experts 
and the information became generally available. While instances of similarities in tumor 
histopathology between the two species have been recorded, the classifications generally lacked 
the granularity needed to satisfy the investigators. The MMHCC classification was merged with 
the NCI vocabularies and no longer exists as an independent taxonomy. The results of each 
pathology committee group were published in refereed journals (Boivin et al. 2003; Hruban et al. 
2006; Ittmann et al. 2013; Kogan et al. 2002; Morse et al. 2002; Nikitin et al. 2004; Shappell et 
al. 2004; Stemmer-Rachamimov et al. 2004; Washington et al. 2013; Weiss et al. 2002). These 
publications report the comparative pathology for organ specific carcinogenesis for the purpose 
of developing mouse models of cancer.   
 
Computable Terminology: Development and Implementation of the Mouse Pathology 
Ontology (MPATH) for use in Mouse Research 
MPATH is an online structured vocabulary of mutant and transgenic mouse pathological 
lesions and processes (http://bioportal.bioontology.org/ontologies/MPATH). The historical 
motivation for the generation of MPATH was a response to the initiation of a database project, 
funded by the European Commission, to produce a definitive image resource for rodent 
pathology called Pathbase (http://www.pathbase.net ; Schofield et al. 2004). The community 
tasked to develop this resource was drawn from experts in the fields of rodent toxicopathology 
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and human anatomic pathology. This grouping expanded considerably in number and specialty 
as the ontology grew (Schofield et al. 2010). At the time in which MPATH was developed 
(1999-2004) ontologies were being created and implemented for the Mouse Genome Informatics 
(MGI) and related databases covering the areas of gene function, phenotype (Smith et al. 2005b), 
and anatomy (Ringwald et al. 2001). It became clear in these and other areas that standard 
terminologies, computable using biosemantic techniques (Bodenreider et al. 2004; Lord et al. 
2003; Smith et al. 2003) were highly desirable. The ontology that emerged from these efforts, 
MPATH, was manually created by pathologists over a period of a decade from 1999-2010 with 
the help of colleagues from across Europe, North America and Japan.  
Recently MPATH was adopted for the computational capture of gross and microscopic 
anatomic pathology from the primary phenotyping program of the European Mouse Disease 
Clinic (EUMODIC) project (Ayadi et al. 2012) and subsequently the International Mouse 
Phenotyping Consortium’s (IMPC) globally coordinated mutant strain production and 
phenotyping program, and implemented as the terminology in the Jackson Laboratory’s Nathan 
Shock Aging Institute large scale mouse lifespan study (Sundberg et al. 2011; Sundberg et al. 
2016; Yuan et al. 2009). For both projects, further development of the ontology was undertaken 
with changes in the structure of several areas and a large increase in the number of terms 
included, together with an expansion of the textual class definitions.  
MPATH is constructed according to ontological “good practice” rules and is consistent 
with the Open Biological and Biomedical Ontology (OBO) Foundry principles (Smith et al. 
2007).  One criterion adopted from the OBO Foundry is the separation of physical pathological 
entities and pathological processes. Such a separation also facilitates automated reasoning across 
the ontology and integration and interoperability with OBO Foundry ontologies. MPATH 
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therefore consists of two major branches, one containing pathological processes and another 
containing pathological structures. Each branch is itself constructed as a taxonomy of classes 
linked by logical axioms, or relations (Smith et al. 2005a). The majority of axioms in MPATH 
are subclass (or ‘is-a’) relations, asserting that a given class is a subclass of a parental class eg. 
choriocarcinoma ‘is-a’ carcinoma. These axioms allow computational work to be done with the 
data, bridging between different groups and expand how searches are done. The hierarchical 
organization of MPATH will be familiar to anyone with experience of taxonomies, and the 
branches within are derived from traditional histopathological classifications of lesions and 
processes. MPATH does not contain classes representing a “disease”, which often include many 
lesions and have distinct etiological origins; this type of entity is more usefully captured with a 
disease ontology such as the Human Disease Ontology (DO) as described by Kibbe et al. 2015 
(http://www.disease-ontology.org). There are strong arguments, mainly from experience in 
toxicologic pathology, that a descriptive (anatomic) coding rather than diagnostic is the most 
useful way to code and analyze pathology-based observations and in fact MPATH can be used in 
the computational definitions of higher order disease classes from other ontologies such as the 
DO. 
MPATH currently has 888 classes in a hierarchy nine layers deep that may be obtained 
from its repository 
(https://raw.githubusercontent.com/PaulNSchofield/mpath/master/mpath.obo). Currently, over 
90% of the classes have textual definitions. The ontology was specifically designed for use by 
trained histopathologists. However, MPATH has the additional advantage to permit computation 
and is amenable to machine presentation in data capture software (Sundberg et al. 2009). 
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Within a single hierarchy it is not feasible to capture, in a precomposed way, a class for 
every type of lesion of every subtype and stage, for every tissue in which it occurs. This would 
give rise to ontology “bloat” and it becomes very difficult to handle for humans and computers 
alike. To solve this problem, we have included some of the more common precomposed classes 
in MPATH; for example, the names of many neoplasms contain anatomic information such as 
brochioloalveolar adenocarcinoma. For cases where such a precomposed term is not available, 
users are able to use a postcomposition approach. In the postcomposition of ontology classes 
different elements of the description are taken from different ontologies and used to create a 
formal computational statement to describe an observation. In the case of MPATH, classes may 
be combined with those from the mouse adult anatomy ontology (MA; 
https://bioportal.bioontology.org/ontologies/MA), to described the location of the lesion; they 
may then be further qualified with one or more classes that characterize qualities, from the 
Phenotype and Trait Ontology (PATO; http://agroportal.lirmm.fr/ontologies/PATO) (Gkoutos et 
al. 2017).  PATO is an ontology of qualities that qualify or provide formal attributes to an entity 
or a process, such as color, texture, or more complex qualities such as malignancy (Gkoutos et al. 
2005). The PATO subset derived for use for histopathology can be found as a “slim” in the main 
PATO file available on from the code repository (https://raw.githubusercontent.com/pato-
ontology/pato/master/pato.obo). An example of a postcomposed term using PATO, MA, and 
MPATH is shown in Figure 4. 
The computational advantages of using ontologies for terminological coding are very 
significant. At the simplest level the subclass relations provided by the hierarchy allows for 
query expansion and for coding of a less specific parent term when there is some doubt as to 
which term is appropriate. The use of standardized terms – the class labels – allows the ontology 
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to be used for text mining (Hoehndorf et al. 2015) and greatly facilitates the process of coding. 
However, the more important advantages lie in the ability to classify, combine and split lesions 
for analysis. When a large experiment is coded using MPATH (and other ontologies such as 
MA) it becomes possible to quantify the occurrence of specific cancers, as well as all cancers, 
and cancer types automatically, without having to recode or manually recalculate the primary 
coding. Similarly it is possible to compute overrepresentation of particular lesions (Hoehndorf et 
al. 2016), types of lesions or anatomical location of lesions in one group of animals versus 
another. We can use MPATH to precisely calculate the similarity in disease profiles between two 
animals or groups of animals using semantic similarity measures. Furthermore, it becomes 
possible to combine and semantically integrate different datasets that use MPATH for coding 
pathology even if the investigators worked at different levels of granularity or different 
geographic locations. 
Experience of coding a study using MPATH and MA has been very positive. In a large-
scale aging study, conducted on 28 inbred strains, the type and diversity of spontaneous diseases 
that aging mice develop were captured using the Mouse Disease Information System (MoDIS) 
system (Sundberg et al. 2011; Sundberg et al. 2016). In addition to MA and MPATH, the 
terminologies in MoDIS were designed to be extended to take user-defined diagnostic terms, 
such as pseudoxanthoma elasticans (PXE), to allow targeted searches to be done on specific 
disease entities (Sundberg et al. 2009; Sundberg et al. 2010; Sundberg et al. 2008).  A total of 
20,885 different diagnoses were made by the same pathologist from reading approximately 
50,000 slides from 2,000 individual mice, with an average of 12 diagnoses per mouse in the 
study. This data has already been successfully utilized for a series of genome-wide association 
(GWA) and other studies (Berndt et al. 2014; Berndt et al. 2016; Li et al. 2016). Work in 
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progress is generating a comprehensive quantitative survey of disease frequency across the 
lifespan of these strains. 
 
Standardized Histopathology Terminology Implemented by the International Mouse 
Phenotyping Consortium (IMPC) 
 
The IMPC was established in 2011 as a global consortium of large-scale mouse 
production and phenotyping centers (Brown and Moore 2012). It consists of 19 research 
institutions and 5 national funders from 11 countries 
(http://www.mousephenotype.org/data/documentation/aboutImpc#howdoesimpcwork). The 
Consortium’s ten-year goal is to generate a ‘knockout’ mutant for every protein coding gene in 
the mouse genome in an effort to characterize the phenotype(s) that each gene confers. All 
mutant strains as live mice (if available) or cryopreserved sperm and phenotype data are freely 
available to the public, including summary data for a cohort compared with multiple wildtype 
controls. To overcome any potential issue of publication bias, the IMPC’s phenotype data 
includes all negative results as well as positive findings and an automated statistical analysis tool 
(Kurbatova et al. 2015) is used to ensure the validity of the post quality-controlled data made 
available to the research community. The IMPC’s web portal (http://www.mousephenotype.org) 
provides a unified single point of access to the production and phenotyping data and enables 
researchers to formulate hypotheses for biomedical and translational research as well as purpose-
driven preclinical studies. In the past five years, data for more than 4,000 genes have been 
captured by 10 IMPC centers around the world. 
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The IMPC’s standardized phenotyping pipeline has been carefully designed, validated, 
and implemented at each participating center. An International Mouse Phenotyping Resource of 
Standardised Screens (IMPReSS) protocol including procedure, data type description, and 
metadata are available for every test through the IMPC’s portal (http://www.impc.org/impress). 
Cohorts of at least 7 female and 7 male adult mutants from each strain enter the pipeline at 4 
weeks of age. Then a sequential set of clinical phenotyping tests to assay all major adult organ 
systems and most areas of major human disease is performed in order to identify abnormal 
phenotypes of functional, biological, or disease relevance. The majority of IMPC tests are 
mandatory in the pipeline; however several optional tests have been standardized to use by 
individual centers where specialized equipment and expertise is available. At 16 weeks of age, a 
standardized panel of terminal tests, including an optional histopathology test, is done to 
complete the pipeline (Adissu et al. 2014; 
https://www.mousephenotype.org/impress/protocol/276/7 ). 
Similar to all of the clinical and terminal tests that the IMPC phenotyping pipeline uses, 
the histopathology test, and the data it generates, must be high-throughput, robust, and 
standardized to facilitate reliable and reproducible downstream analysis by the global research 
community (Mallon et al. 2012; Ring et al. 2015). Histopathology has always played a pivotal 
role in hypothesis-driven studies, purpose-driven translational investigations, and preclinical 
assessment of mouse models, providing important insight into the morphological (structural) 
consequences and mechanisms of gene function or dysfunction and therapeutic effect and safety. 
In the context of the IMPC’s high-throughput phenotyping pipeline, the histopathology test’s 
objectives using a panel of tissues (25 required for female mice; 26 required for male mice) 
collected from 2 female and 2 male mutant mice from each strain are to:  
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1) Identify abnormalities (‘lesions’) correlated with clinical phenotype (e.g. clinical 
ataxia, cerebellar histopathology). 
2) Identify significant abnormalities not directly correlated with clinical phenotype, often 
the result of gene pleiotropy whereby a single mutate gene causes multi-system changes (e.g. 
clinical ataxia, liver histopathology). 
3) Identify significant abnormalities that are novel findings in strains with no identified 
clinical phenotype. 
4) Classify any of these findings as ‘not significant’ (interpreted by the histopathologist 
to be background-related or incidental) or ‘significant’ (interpreted by the histopathologist to not 
be a background-related finding; e.g., low-incidence retinal dysplasia) or incidental finding (e.g., 
focal hepatic microgranuloma). 
To achieve the same objectives for histopathology data of standardization, quality-
control, and semantic standards (i.e. machine-search ability by web portal users) required by the 
IMPC, the Consortium’s Morphology Working Group has developed a histopathology ontology 
that is a compilation of three well-established ontologies described in other sections of this 
paper; MA, PATO, and MPATH. The data capture, annotation, and storage system developed at 
The Centre for Phenogenomics (TCP; http://www.phenogenomics.ca) in Toronto is provided as 
an example of integration, implementation, and use of the IMPC histopathology ontology within 
an IMPC center. Briefly, TCP histopathology data acquisition work flow supported by the 
system’s user interface (Figure 5) and integration of MA, PATO, and MPATH ontologies within 
the database typically includes several steps:  
1) Select a mouseID on the worklist for review.  
2) The required tissue list is auto-populated.  
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3) Each individual tissue row includes the MA term name and term ID (e.g. liver 
[MA:00003581]) and entry fields with dropdown lists to select PATO descriptors (Severity, 
Duration, Distribution), MPATH Process Terms (e.g. inflammation [MPATH:212]), and 
MPATH Diagnosis (entity) Terms (e.g. granuloma [MPATH:847]).  
4) Add Free Text Diagnostic Term if necessary, add Pathologist Comments if 
appropriate, and toggle the Significance Score check-box (i.e. unchecked equals Not Significant, 
checked equals Significant).  
Note that certain Term fields are auto-populated for efficient workflow (if no findings to 
annotate, no entry effort required) and to comply with the minimum required dataset for 
successful upload to the IMPC Data Center. Additional functionality includes parsed dropdown 
lists (e.g., liver row’s MPATH Process Terms and MPATH Diagnostic Terms only provide term 
options applicable to liver pathology) (Figure 6). 
The IMPC histopathology ontology described here is fully integrated in the IMPC’s 
central database. Therefore, any center in the Consortium that is doing histopathology at 
IMPReSS standards can upload data compliant with the standardization, quality-control, and 
machine-readable requirements of the IMPC. Using MA, PATO, and MPATH, each well 
established, publically available, and actively curated extant ontologies was, and is, essential to 
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Figure 4. Schematic diagram describing post-composition strategy for lesions. Classes are taken 
from PATO, MPATH and MA and combined to form a formal statement describing the lesion 
and its location. A similar process may be used for gross pathology as well; PATO contains 
appropriate macroscopic qualifiers for this purpose, such as colour, texture, size and shape.  
 
Figure 5. Screen shot of TCP’s histopathology data entry user interface used to annotate IMPC 
strains. 
 
Figure 6. Screen shot of TCP’s histopathology data entry user interface. Note in the example for 
annotating a liver section, the dropdown selection list for MPATH Process Terms provides only 
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Figure 6. Screen shot of TCP’s histopathology data entry user interface. Note in the example for annotating 
a liver section, the dropdown selection list for MPATH Process Terms provides only terms applicable to liver 
histopathology.  
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